Cambridge and London, UK: 14 September 2021
One Nucleus, the non-for-profit Life Science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes. Supporting companies throughout their life cycle. This includes facilitating connections between entrepreneurs and company-makers, including investors. Deep Science Ventures (DSV) operate across multiple sectors combining world-leading knowledge, talent and investment to form high impact new…
Leading pharmaceutical and biotech product development consultancy Boyds has announced the opening of its US office in the Philadelphia area and welcomes Katy Rudnick who is appointed Vice President and Head of US Regulatory Affairs to head up the newly established US company.
Since Boyds was established in 2005, the company has worked with US companies seeking to develop and gain approval for their medicines in Europe and further afield. Boyds’ global reputation for its work in advanced therapies has led to a steady increase in the number of companies approaching Boyds for this expertise,…
Cambridge, UK, 9 September 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes.The IND supports a Phase I clinical trial in the US in approximately 24 participants with type I diabetes, to further explore the clinical benefits of AT247. The trial is a double blind, randomised, three…
In this trial of preliminary issues, Zacaroli J held that when assessing the damages payable to multiple claimants under cross-undertakings given in respect of various interim injunctions and orders (and for unjustified threats of patent infringement), a single set of counterfactual assumptions should apply to all inquiry claimants, where those claimants operate in the same, largely finite, market. The decision is the latest in a long line of judgments concerning Pfizer’s pregabalin product, Lyrica®.
Pfizer held the marketing authorisation for pregabalin (branded Lyrica®) and Warner-Lambert (…
Cambridge, UK, 07 September 2021– Arecor Therapeutics plc, the biopharmaceutical group which is advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd (“Intas”).
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated product for Intas. The new product formulation supports improved usability for the patient compared to current marketed products and in particular facilitates home use outside of a healthcare environment. Intas will…
NORWICH, UK – 07 September 2021: Leaf Expression Systems (Leaf), a biotechnology company specialising in plant-based expression, today announced the launch of SupraVecTM, Leaf’s new proprietary vector-based expression technology for the rapid production of proteins, vaccines and complex biomolecules within the leaf tissue of plants.
SupraVecTM is a plant transient expression system designed with novel expression components to optimise yields. The expression technology delivers a three-fold improvement in the yield compared to Leaf’s previous pEAQ-HT system, also known as Hypertrans® (figure 1…
Today marks the official opening of our operations in Dublin, and our 29th office worldwide.
Plans to open in Ireland were announced earlier this year with the appointment of the firm's latest partner hires.
Opening in Dublin presents new opportunities for clients including large organisations, start-ups, investors and entrepreneurs across Europe and the US, especially in life sciences and healthcare and technology sectors, which the firm is recognised for.
Adam Griffiths, who was previously a member of the firm's Private Equity team and relocated to Ireland in 2017, has returned to…
Babraham, 06 September 2021: Babraham Bioscience Technologies Ltd, which manages and develops the Babraham Research Campus on behalf of its shareholders - BBSRC and the Babraham Institute – is now known as Babraham Research Campus Ltd.The name change more clearly reflects the activity of the organisation and is also in response to the refreshed and ambitious vision for the Campus announced in May this year.Jo Parfrey, Chair of the Babraham Research Campus Board, says: “The new identity signals our ongoing focus on the world-class bioscience Campus at the…
The UK Court of Appeal has reviewed the law on insufficiency and its application to claims with both structural and functional limitations. In doing so the court has explained how the concepts of plausibility and undue burden should be applied when assessing the sufficiency of claims of this type, in particular to the requirement that it must be possible to perform the invention across the breadth of the claim.
The appeal concerned six patents belonging to FibroGen, which had been divided into two “families”. The court had to consider issues of obviousness and infringement, as well as…
Germany has finally ratified the Unified Patent Court Agreement, its Constitutional Court having rejected two applications for a preliminary injunction to prevent ratification. This removes a significant hurdle to the commencement of the Unified Patent Court (UPC) system but that is not to say that it will start any time soon. The UPC preparatory committee, which consists of representatives the countries which signed the UPC Agreement back in 2013, estimates that the UPC will start operating in mid-2022. It is certainly unlikely that the UPC will start its operations before then but it may…